| 產(chǎn)品名稱 | CHO DP-12 clone#1934 [CHO DP-12, clone#1934 aIL8.92 NB 28605/14] |
|---|---|
| 商品貨號 | B181379 |
| Organism | Cricetulus griseus, hamster, Chinese |
| Tissue | ovary |
| Product Format | frozen |
| Morphology | fibroblast |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Storage Conditions | liquid nitrogen vapor phase |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Images |  |
| Derivation | The clone#1934 aIL8.42 NB 28605/14 cell line was derived by co-transfecting the CHO cell line DP-12 using Lipofection with the vector p6G4V11N35E.choSD.10 designed to coexpress variable light and heavy regions of the murine 6G4.2.5 monoclonal antibody (ATCC HB-11722). Clones were selected in methotrexate. |
| Comments | The cells are reported to produce 250 mg/L recombinant human anti-IL-8. Both the clone#1933 (ATCC CRL-12444) and clone#1934 (ATCC CRL-12445) antibodies inhibit IL-8 binding to human neutrophils. They also show equivalent neutralizing capabilities to inhibiting IL-8 mediated human neutrophil chemotaxis. The mammalian expression plasmid, p6G4V11N35AchoSD.9 (identified as p6G425V11N35A.choSD is deposited as ATCC 209552). |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: 200 nM methotrexate, 0.002 mg/ml recombinant human insulin, Trace Elements A (Cellgro) to a final concentration of 0.1%, Trace Elements B (Cellgro) to a final concentration of 0.1%, fetal bovine serum to a final concentration of 10%
|
| Subculturing | Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended
Medium Renewal: Two to three times weekly |
| Cryopreservation | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| Isotype | human IgG1 |
| Name of Depositor | Genetech, Inc. |
| U.S. Patent Number | |
| Year of Origin | 1934 |
| References | Hsei V, et al. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,468,532 dated Oct 22 2002 Hsei V, et al. Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates. US Patent 6,458,355 dated Oct 1 2002 Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,133,426 dated Oct 17 2000 Gonzalez TN, et al. Humanized anti-IL-8 monoclonal antibodies. US Patent 6,117,980 dated Sep 12 2000 Gonzalez TN, et al. Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies. US Patent 6,025,158 dated Feb 15 2000 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
